IMS views reimbursement approaches that may limit access to innovative cancer treatments

30 March 2015
lab-testing-big

Even as the surge in innovative oncology medicines yields new therapeutic options for a growing number of cancer patients, different approaches to reimbursement by health systems across the globe are likely having an impact both on patient access to transformative treatments and overall care, according to a new report from the IMS Institute for Healthcare Informatics.

In five countries examined where health care agencies adopt more rigid cost-effectiveness thresholds to determine reimbursement levels for oncology medicines, the study found that fewer new cancer drugs are being reimbursed, reimbursement decisions are taking longer and new cancer drugs are being adopted more slowly and at lower rates.

The report – Impact of Cost-per-QALY Reimbursement Criteria on Access to Cancer Drugs – considers the implications of reimbursement for nine new cancer drugs in five countries that have adopted a “cost per quality-adjusted life year” (CPQ) reimbursement approach (England, Scotland, Sweden, Australia and Canada), and compares those results with five non-CPQ countries (USA, France, Germany, Italy and Spain). CPQ methodologies apply a standardized measure of value to determine treatment reimbursement levels, including an analysis of the clinical, social and economic value of a treatment. Non-CPQ approaches primarily assess a new drug’s clinical effectiveness and the health gain for patients, rather than comparing patient outcomes against a standard cost-effectiveness metric or threshold.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical